Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era
Authors: Gunnarsson Niklas , Leif Stenke , Höglund Martin , Sandin Fredrik , Björkholm Magnus , Dreimane Arta , Lambe Mats , Markevärn Berit , Olsson-Strömberg Ulla , Richter Johan , Wadenvik Hans , Wallvik Jonas , Själander Anders 
Published: October 2019

Background: Since continuous treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved the survival of patients with chronic myeloid leukemia (CML), it is of interest to examine the possible risk of long-term adverse events. Previous studies have presented conflicting results regarding risk of second malignancies. Our aim was to examine the development of second malignancies (except acute myeloid or lymphoblastic leukemia, myelodysplastic syndromes or non-melanoma skin cancer) in CML chronic phase patients diagnosed after the introduction of TKI treatment.

Materials and methods: We studied the development of second malignancies in 868 patients diagnosed with CML in chronic phase 2002 to 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. Each patient was followed from the time of CML diagnosis until death from any cause, date of allogeneic hematopoietic stem cell transplantation (SCT) or end of study on December 31, 2011, whichever came first. SCT was used as an endpoint because of the well established increased risk of second malignancies after this procedure. Standardized Incidence Ratios (SIR) were calculated to assess the risk of a second malignancy by dividing the number of observed second malignancies with the number of expected malignancies in the Swedish population, using data from the Swedish Cancer Register. The expected numbers of malignancies were determined by dividing the CML population according to 5-year age groups, sex, region of residence (6 regions) and calendar year. The number of person-years in each stratum was multiplied with the incidence of malignancies or deaths found in the corresponding strata in the general population.

Results: With a median follow-up of 3.7 (range 0-9.9) years, 65 (7.5%) patients developed 75 second cancers (non-hematologic), 49 of these of invasive type. Compared to expected rates in the background population matched by age, sex, region of residence (6 regions) and calendar year, the risk of second malignancies was significantly higher in the CML cohort, with a Standardized Incidence Ratio (SIR) of 1.5 (95 % CI 1.13-1.99). SIR before and after the second year following diagnosis of CML was 1.6 (95 % CI 1.004-2.38) and 1.5 (95 % CI 0.98-2.11), respectively. Looking at CML subpopulations, the increased risk of developing a second malignancy reached statistical significance for females (SIR: 1.8; 95 % CI 1.18-1.99), but not for males (SIR: 1.3; 95 % CI 0.85-1.91), and for patients above 60 years of age at diagnosis (SIR: 1.5; 95 % CI 1.05–1.96). Assessment of risk by cancer type was hampered by small numbers. However, the data at hand indicate an increased risk for gastrointestinal cancer (SIR: 3.0; 95 % CI 1.60-5.16), as well as nose and throat cancer (SIR: 37.1; 95 % CI 7.46-108.40), table 1.

Conclusions: Utilizing large, population-based registries with data accumulated during the TKI era, our results indicate that CML patients, compared to the normal control population, are at an 50% increased risk of developing a second malignancy. Similar SIR before and after the second year following the diagnosis of CML may indicate that these findings are linked to the CML disease itself, rather than to the TKI treatment. Further studies and longer follow-up seem however warranted. Physicians caring for CML patients should be aware of signs and symptoms of other malignancies in this patient population.

Table 1 Standardized Incidence Ratios for second malignancies (excluding cases of non-melanoma skin cancer, AML, ALL and MDS) among 868 Swedish CML patients diagnosed between 2002 and 2011. Total follow up time 3293 person-years (median 3.7 years). Variable Observed Expected SIR (Observed/Expected) 95 % CI for SIR Overall 52 34 1.5 1.13–1.99 Men 26 20 1.3 0.85–1.91 Women 26 14 1.8 1.18–2.66 Age <60 years 10 5 1.9 0.89–3.42 Age ³ 60 years 42 28 1.5 1.05–1.96 Second cancer type Prostate 14 8 1.8 0.96–2.94 Gastrointestinal 13 4 3.0 1.60–5.16 Gynecological 4 1 3.6 0.98–9.30 Nose and Throat 3 0,1 37.1 7.46-108.40 Lung 2 2,7 0.7 0.08-2.67 Breast 4 4,2 0.98 0.26-2.45

Disclosures

Björkholm: Novartis: Research Funding; Shire: Research Funding; Merck: Research Funding; Amgen: Honoraria, Research Funding; Pfizer: Research Funding; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Akinon: Honoraria; Nordic Nanovector: Honoraria. Richter:Ariad: Honoraria; Bristol-Myers Squibb: Honoraria; Novartis: Honoraria. Själander:Novartis: Honoraria.